Free Trial
NASDAQ:NXTC

NextCure Q4 2024 Earnings Report

NextCure logo
$0.51 +0.01 (+2.15%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.50 -0.01 (-1.73%)
As of 05/23/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.34
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, March 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

NextCure's Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled on Friday, August 1, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

NextCure Earnings Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

View NextCure Profile

More Earnings Resources from MarketBeat